HLA-C and neoplasm: The potential cause of this poor efficacy comprises a range of factors adverse to immunotherapy, such as low number of tumour infiltrating lymphocytes, low expressions of PD-L1 and MHC class, presence of immunosuppressive cell populations and cytokines, as well as avascular tumour areas from rapid tumour growth for immune evasion [86].